GCell — The Dual-Purpose Tissue Processing Platform For Cellular Therapy
One intelligent device. Two physician-directed applications. The GCell Autologous Tissue Separation System by RenuvoGen delivers same-session, point-of-care tissue processing for both Mechanical Tissue Washing & Concentration and Autologous Tissue-Supported Hair Growth — setting a new standard in precision tissue preparation.
What Is the GCell?
A Closed-Loop Mechanical Tissue Processing Device
The GCell is a FDA cleared, closed-loop, tissue processing device designed for point-of-care preparation of a patient's own tissue (adipose & hair). Through mechanical slicing, mincing, filtration, washing, and centrifugation — with no enzymatic digestion and no chemical additives — GCell refines and concentrates autologous tissue for same-session, physician-directed use.
During this process, the tissue's naturally occurring cellular components — including AD-MSCs, pericytes, stromal vascular fraction elements, and signaling cytokines — become naturally concentrated within the resulting graft. Its compact, tabletop form factor fits seamlessly into clinic environments — no cleanroom infrastructure required.
Two Applications. One Device.
The GCell's versatile closed-system architecture supports two distinct — and highly sought-after — tissue processing applications, allowing clinics to maximize their investment and serve a broader patient population.
Mechanical Tissue Washing & Concentration
Mechanically process and concentrate a patient's own adipose tissue through closed-loop filtration, washing, and centrifugation — naturally concentrating AD-MSCs, pericytes, stromal vascular fraction elements, and signaling cytokines for same-session, physician-directed structural use.
Autologous Tissue-Supported Hair Growth
Mechanically process biopsied hair-bearing or adipose tissue for physician-directed scalp applications — supporting hair growth through the natural concentration of the tissue's own cellular components, without enzymatic digestion or chemical additives.
The Science of Tissue Separation
During GCell's mechanical tissue processing — slicing, mincing, filtration, washing, and centrifugation — the tissue's naturally occurring cellular components become concentrated within the resulting graft. This natural concentration effect, not an isolated or purified stem cell product, is what makes the processed tissue valuable for supporting structural repair, cushioning, and the body's healing environment.
Immunomodulatory Effects
The tissue's naturally concentrated cellular components — including AD-MSCs and pericytes — may support the body's inflammatory response and create a favorable environment for structural repair and cushioning.
Multipotent Differentiation
Adipose-derived mesenchymal stem cells (AD-MSCs) naturally present in the tissue are multipotent progenitor cells that become concentrated during mechanical processing — contributing to the graft's structural and biological properties.
Paracrine Signaling
Signaling cytokines, growth factors, and extracellular matrix components naturally present in adipose tissue are preserved and concentrated during GCell's mechanical processing — supporting the body's own healing environment.
Structural Support & Tissue Handling
The refined, micro-fragmented autologous tissue graft provides structural cushioning and volume filling — performing the same basic functions in the recipient that the tissue naturally performs in the body.
Mechanical Tissue Washing & Refinement
GCell mechanically processes a patient's own adipose tissue through a fully closed, sterile system — washing, sizing, filtering, and centrifuging the tissue to reduce blood, oils, fluid byproducts, and debris while preserving the tissue's native architecture. During this process, the tissue's naturally occurring cellular components — including AD-MSCs, pericytes, stromal vascular fraction elements, extracellular matrix components, and signaling cytokines — become naturally concentrated within the resulting graft. No enzymatic digestion, no collagenase, no trypsin, no chemical additives. The refined autologous tissue is ready for same-session, physician-directed use in as little as 60–90 minutes — entirely at the point of care.
Clinical Applications for Processed Autologous Tissue
Orthopedics & Structural Support
Physician-directed use of refined autologous tissue in and around joints may support structural cushioning and the body's natural healing environment. GCell's same-session processing enables point-of-care tissue preparation without external laboratory transfer.
Aesthetic & Volume Restoration
Refined autologous tissue processed with GCell can be used alongside fat grafting to support volume filling and structural support in aesthetic procedures — performing the same basic cushioning and filling functions that adipose tissue naturally provides in the body.
Wound Care & Tissue Handling
Physician-directed application of mechanically processed autologous tissue may support the body's healing environment in wound care and post-surgical settings, providing structural support and cushioning where tissue handling is indicated.
How GCell Processes Tissue — Step by Step
Mini-Liposuction or Biopsy Graft
Harvest adipose tissue or hair graft under local anesthesia via closed sterile entry.
Mechanical Processing
Tissue is mechanically sliced, minced, filtered, and washed inside the closed GCell chamber — no enzymes, no chemical additives.
Centrifugation & Refinement
Centrifugation separates and concentrates the refined autologous tissue, reducing blood, oils, and fluid byproducts while preserving native architecture.
Same-Session Use
Refined tissue is delivered at the point of care within the same procedure — no external lab transfer required.
The entire process occurs within a fully closed, sterile system — with no enzymatic digestion, no collagenase, no trypsin, and no chemical additives.
No external laboratory transfer is required, enabling same-session, point-of-care tissue preparation in a standard procedure room.
Hair Restoration Protocol Overview
Patient Consultation & Assessment
Evaluate hair loss pattern (Norwood/Ludwig scale), scalp health, and candidacy. Document baseline hair density with trichoscopy or digital imaging for outcome tracking.
Tissue Harvest & GCell Processing
Perform hair biopsy or micro-liposuction (typically abdominal or flank region) under local anesthesia. Process tissue through the GCell via mechanical slicing, filtration, washing, and centrifugation — with no enzymatic digestion or chemical additives — yielding refined, concentrated autologous tissue within 60 minutes or less.
Physician-Directed Scalp Application
The refined autologous tissue is applied via micro-injections across the treatment zone using a fine-gauge mesotherapy technique during the same session. The entire application typically takes 30–45 minutes.
Follow-Up & Repeat Sessions
Patients are likely to observe changes in hair density and thickness over time following physician-directed treatment. A protocol of 1–3 sessions may be recommended based on individual assessment and physician judgment.
Autologous Tissue-Supported Hair Growth
Hair loss affects an estimated 80 million Americans, yet most existing approaches address only surface-level symptoms. GCell offers physicians a same-session, point-of-care option: mechanically processing a patient's own adipose or hair-bearing tissue to yield a refined autologous graft — naturally concentrated with AD-MSCs, pericytes, extracellular matrix components, and signaling cytokines — for physician-directed scalp application.
The process uses no enzymatic digestion, no chemical additives, and no cell culturing. The refined tissue is applied during the same procedure, supporting the body's own structural and healing environment at the scalp.
The Science Behind GCell Tissue Processing for Scalp Applications
Why Autologous Tissue Processing Matters
During GCell's mechanical processing, the tissue's naturally occurring adipose-derived mesenchymal stem cells (AD-MSCs) — along with pericytes, stromal vascular fraction elements, extracellular matrix components, and signaling cytokines including VEGF, HGF, KGF, and IGF-1 — become naturally concentrated within the refined graft.
This natural concentration of the tissue's own cellular and structural components — not a purified or cultured cell product — is what makes the resulting graft valuable for supporting the body's structural and healing environment at the scalp.
Key Biological Components
VEGF & signaling cytokines — Naturally present in adipose tissue and concentrated during mechanical processing
Extracellular matrix components — Preserved through mechanical-only processing with no enzymatic digestion
Anti-inflammatory cellular components — AD-MSCs and pericytes naturally present in the concentrated graft
Native tissue architecture — Maintained throughout — no collagenase, no trypsin, no chemical additives
Clinical Outcomes: Autologous Tissue-Supported Scalp Applications
Published clinical data and physician-reported outcomes from GCell-based autologous tissue processing protocols demonstrate patient-reported improvements across key functional endpoints.
Patient Satisfaction
Reported satisfaction with hair density changes at 6-month follow-up in multi-center observational data from physician-directed autologous tissue protocols
Follicle Count Changes
Increase in active follicle count versus baseline documented via trichoscopy in autologous tissue scalp application cohorts
Procedure Time
Average total procedure time from harvest to same-session scalp application — enabling point-of-care, outpatient treatment
Donor Rejection
Zero immunological rejection events — autologous origin eliminates compatibility risk entirely
GCell vs. Traditional Approaches
Understanding how GCell compares to conventional tissue processing and hair-support modalities clarifies its compelling clinical and operational advantages.
Device Specifications & Features
GCell Technical Overview
Closed-Loop System
Fully sterile, single-use processing cartridge — zero cross-contamination risk between patients. No enzymatic digestion, no chemical additives.
Processing Capacity
Handles 50–300cc lipoaspirate input; yields refined, micro-fragmented autologous tissue concentrate depending on input volume
Processing Time
Complete mechanical tissue processing in 60–90 minutes — enabling same-session, point-of-care tissue preparation within a standard procedure room
Regulatory Status
FDA cleared and compact tabletop design requires no laboratory infrastructure or cleanroom setup. Operates within the same-surgical-procedure autologous tissue framework.
Why Leading Clinics Choose GCell
Enhanced Patient Treatments
Autologous tissue processing with GCell offers patients a same-session, point-of-care experience using their own tissue — with no donor compatibility concerns and no external laboratory transfer — giving your clinic a clinically differentiated premium therapy for clients.
Expand Revenue Streams
A single GCell system opens two high-value tissue processing service lines — mechanical tissue washing & concentration and autologous tissue-supported hair growth — without duplicating capital equipment investment. One device, two compelling physician-directed applications.
Minimize Regulatory Risk
GCell's closed-loop, mechanical-only processing system — with no enzymatic digestion, no chemical additives, and no cell culturing — supports a favorable regulatory posture in most markets. No allogeneic product licensing, no cleanroom requirements, no complex chain-of-custody documentation.
Streamlined Same-Day Procedures
The 90-minute point-of-care protocol fits within a half-day clinical slot. No patient return visits for laboratory results, no external processing delays — just efficient, same-session tissue preparation and physician-directed application.
Real Physicians. Real Results.
Physicians across orthopedics, plastic surgery, and aesthetic medicine have integrated GCell's point-of-care tissue processing into their practice with consistently strong patient experiences.
"GCell has transformed how we approach scalp applications in our practice. The ability to offer patients their own mechanically processed tissue — prepared in-house, same session — is a genuine clinical differentiator. Our patients appreciate the autologous, point-of-care approach and the streamlined experience."
— Dr. M. Yilmaz, MD, Aesthetic Medicine & Hair Restoration Specialist
"The tissue quality from GCell is consistently high. For our orthopedic patients who aren't ready for surgery, this same-session autologous tissue processing protocol has become a valuable point-of-care option. The closed-system design gives us confidence in sterility and reproducibility."
— Dr. A. Kaya, MD, Orthopedic Surgery & Regenerative Medicine
Training, Support & Implementation
🎓 Clinical Training Program
RenuvoGen provides comprehensive hands-on training for physicians and clinical staff — covering patient selection, harvest technique, GCell mechanical processing protocol, and physician-directed tissue application methodology for both tissue washing & concentration and autologous tissue-supported hair growth applications.
🔬 Protocol & Marketing Support
Receive ready-to-use clinical protocols, patient consent documentation, treatment tracking templates, and co-branded marketing materials — all reviewed for FDA-compliant language — to help you launch and grow your point-of-care tissue processing service line quickly and confidently.
📞 Ongoing Clinical Consultation
Our medical affairs team is available to provide case consultation, outcome review, and continuous education as the clinical evidence base for autologous tissue processing evolves. We're your long-term precision tissue processing partner.
Frequently Asked Questions
Is GCell FDA-cleared?
GCell is FDA cleared for use in U.S.markets. The device operates within the FDA's enforcement discretion policy for same-surgical-procedure autologous tissue use — satisfying the standards of minimal manipulation, homologous use, no chemical additives, and same-session processing. Speak with your RenuvoGen representative for full regulatory details.
How much adipose tissue is required?
A minimum of approximately 100cc of lipoaspirate is sufficient for most scalp application sessions. Tissue washing & concentration protocols for orthopedic or aesthetic applications may require 100–200cc depending on the treatment target and desired tissue yield.
Can GCell be used alongside other treatments?
Yes. Mechanically processed autologous tissue from GCell is frequently used alongside PRP, hyaluronic acid, microneedling, LLLT (low-level laser therapy), and fat grafting as part of physician-directed protocols. All combination use should be evaluated by the treating physician.
Does this involve stem cell injections?
GCell mechanically processes a patient's own tissue — it does not isolate or extract stem cells as a standalone drug product. During mechanical washing, sizing, and centrifugation, the tissue's naturally occurring cellular components (including AD-MSCs and other progenitor cells) become naturally concentrated within the refined graft. The processed tissue is reintroduced into the same patient during the same procedure.
Ready to Elevate Your Practice?
Join the growing network of forward-thinking clinics offering GCell-powered point-of-care tissue processing for both mechanical tissue washing & concentration and autologous tissue-supported hair growth applications. RenuvoGen provides the device, the training, the FDA-compliant clinical protocols, and the ongoing support to make your launch seamless and your patient experience exceptional.
📋 Request Clinical Information
Download our full product dossier, clinical evidence compendium, and procedure guides
🏥 Schedule a Virtual Demo
See the GCell system in action with a personalized demonstration at your clinic or our showroom
💬 Speak to a Specialist
Connect directly with a RenuvoGen clinical specialist to discuss your practice goals and patient population